Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onivyde

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

- PMLiVE

Ipsen bolsters leadership team

Ivana Magovcevic-Liebisch and Régis Mulot join the biopharma

- PMLiVE

Dr Sotirios Stergiopoulos leaves Shire for Ipsen

He becomes the French biopharma’s chief medical officer

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

- PMLiVE

Richard Paulson joins Ipsen as CEO for North America

He also becomes an executive vice-president at the French biopharma

- PMLiVE

Ipsen appoints Aidan Murphy as EVP, technical operations

He is promoted from senior VP biologics development and manufacturing

- PMLiVE

Accelerating innovation

Ipsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach

- PMLiVE

Ipsen promotes Alexis Vandier as general manager, France

He will also join the French biopharma group’s global speciality leadership team

- PMLiVE

Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication

- PMLiVE

Ian Weatherhead joins Ipsen

Takes up corporate communications role at the French pharma firm

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

NICE gives green light to Ipsen’s Cabometyx

Backs the medicine’s use for patients with advanced kidney cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links